Viral-toxin interactions and Parkinson's disease: Poly(I:C) priming enhanced the neurodegenerative effects of paraquat

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Bobyn, Jessica ^a   Mangano, Emily N ^a   Gandhi, Anusha ^a   Nelson, Eric ^a   Moloney, Kerry ^a   Clarke, Melanie ^a   Hayley, Shawn ^a  

^a CARLETON UNIVERSITY   (Canada)

Author keywords

Cytokine; Microglia; Neurodegeneration; Neuroinflammation; Pesticide; Viral

Indexed keywords

PARAQUAT; POLYINOSINIC POLYCYTIDYLIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; VIRUS ANTIGEN;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE EXACERBATION; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL EXPOSURE; MALE; MICROGLIA; MOUSE; NERVE CELL STIMULATION; NERVE DEGENERATION; NERVE ENDING; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN EXPRESSION; RNA VIRUS; SUBSTANTIA NIGRA PARS COMPACTA; SUBVENTRICULAR ZONE; TOXIN ANALYSIS;

EID: 84860521417     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-86     Document Type: Article

References (63)

1. Lev N, Melamed E, Offen D. Apoptosis and Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:245-250. 10.1016/S0278-5846(03)00019-8, 12657363.
2. McCoy MK, Cookson MR. Mitochondrial quality control and dynamics in Parkinson's disease. Antioxid Redox Signal in press.
3. McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P. Failure of the ubiquitin-proteosome system in Parkinson's disease. Nat Rev Neurosci 2001, 2:589-594.
4. Nagatsu T, Mogi M, Ichinose H, Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl 2000, 60:277-290.
5. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999, 22:123-144. 10.1146/annurev.neuro.22.1.123, 10202534.
6. McGeer PL, McGeer EG. Glial reactions in Parkinson's disease. Mov Disord 2008, 23:474-483. 10.1002/mds.21751, 18044695.
7. Nagatsu T, Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des 2005, 11:999-1016. 10.2174/1381612053381620, 15777250.
8. Tufekci KU, Genc S, Genc K. The endotoxin-induced neuroinflammation model of Parkinson's disease. Parkinsons Dis 2011, 2011:487450. 3034925, 21331154.
9. Ling Z, Zhu Y, Tong C, Snyder JA, Lipton JW, Carvey PM. Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally. Exp Neurol 2006, 199:499-512. 10.1016/j.expneurol.2006.01.010, 16504177.
10. Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 2007, 208:1-25. 10.1016/j.expneurol.2007.07.004, 17720159.
11. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: the dual hit theory revisited. Ann N Y Acad Sci 2009, 1170:615-622. 10.1111/j.1749-6632.2009.04365.x, 19686202.
12. Mangano E, Hayley S. Inflammatory priming of the substantia nigra influences the impact of later paraquat exposure: neuroimmune sensitization of neurodegeneration. Neurobiol Aging 2009, l30:1361-1378.
13. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 2007, 30:244-250. 10.1016/j.tins.2007.03.009, 17418429.
14. Ling Z, Chang QA, Tong CW, Leurgans SE, Lipton JW, Carvey PM. Rotenone potentiates dopamine neuron loss in animals exposed to lipopolysaccharide prenatally. Exp Neurol 2004, 190:373-383. 10.1016/j.expneurol.2004.08.006, 15530876.
15. Okun E, Griffioen KJ, Lathia JD, Tang SC, Mattson MP, Arumugam TV. Toll-like receptors in neurodegeneration. Brain Res Rev 2009, 59:278-292. 10.1016/j.brainresrev.2008.09.001, 2679904, 18822314.
16. Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 2004, 173:3916-3924.
17. Trudler D, Farfara D, Frenkel D. Toll-like receptors expression and signaling in glia cells in neuro-amyloidogenic disease: towards future therapeutic application. Mediators Inflamm 2010, 2010:497987. 2913815, 20706642.
18. Hamanaka J, Hara H. Involvement of Toll-Like Receptors in Ischemia-Induced Neuronal Damage. Cent Nerv Syst Agents Med Chem 2009, in press.
19. Landreth GE, Reed-Geaghan EG. Toll-like receptors in Alzheimer's disease. Curr Top Microbiol Immunol 2009, 336:137-153. 10.1007/978-3-642-00549-7_8, 3032986, 19688332.
20. Racke MK, Drew PD. Toll-like receptors in multiple sclerosis. Curr Top Microbiol Immunol 2009, 336:155-168. 10.1007/978-3-642-00549-7_9, 3064511, 19688333.
21. Casals J, Elizan TS, Yahr MD. Post-encephalitic parkinsonism-a review. J Neural Transm 1998, 105:645-676. 10.1007/s007020050086, 9826109.
22. Dickman MS. Von economo encephalitis. Arch Neurol 2001, 58:1696-1698. 10.1001/archneur.58.10.1696, 11594935.
23. Jang H, Boltz D, Sturm-Ramirez K, Shepherd KR, Jiao Y, Webster R, Smeyne RJ. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci U S A 2009, 106:14063-14068. 10.1073/pnas.0900096106, 2729020, 19667183.
24. Ravenholt RT, Foege WH. 1918 influenza, encephalitis lethargic, parkinsonism. Lancet 1982, 2:860-864.
25. Deleidi M, Hallett PJ, Koprich JB, Chung CY, Isacson O. The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration. J Neurosci 2010, 30:16091-16101. 10.1523/JNEUROSCI.2400-10.2010, 3075577, 21123556.
26. Brooks AI, Chadwick CA, Gelbard HA, Cory-Slechta DA, Federoff HJ. Paraquat elicited neurobehavioural syndrome caused by dopaminergic neuron loss. Brain Res 1999, 823:1-10. 10.1016/S0006-8993(98)01192-5, 10095006.
27. Mangano EN, Peters S, Litteljohn D, So R, Bethune C, Bobyn J, Clarke M, Hayley S. Granulocyte macrophage-colony stimulating factor protects against substantia nigra dopaminergic cell loss in an environmental toxin model of Parkinson's disease. Neurobiol Dis 2011, 43:99-112. 10.1016/j.nbd.2011.02.011, 21377529.
28. Crocker SJ, Smith PD, Jackson-Lewis V, Lamba WR, Hayley SP, Grimm E, Callaghan SM, Slack RS, Melloni E, Przedborksi S, Robertson GS, Anisman H, Merali Z, Park DS. Inhibition of calpains prevents neuronal and behavioural deficits in an MPTP mouse model of Parkinson's disease. J Neurosci 2003, 23:4081-4091.
29. Litteljohn D, Mangano E, Hayley S. Cyclooxygenase-2 deficiency modifies the neurochemical effects, motor impairment and co-morbid anxiety provoked by paraquat administration in mice. Eur J Neurosci 2008, 28:707-716. 10.1111/j.1460-9568.2008.06371.x, 18657183.
30. Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RK. MPTP susceptibility in the mouse: behavioural, neurochemical and histological analysis of gender and strain differences. Behav Genet 2000, 30:171-182. 10.1023/A:1001958023096, 11105391.
31. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000, 3:1301-1306. 10.1038/81834, 11100151.
32. Costello S, Cockburn M, Bronstein J, Zhang X, Ritz B. Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol 2009, 169:919-926. 10.1093/aje/kwp006, 2727231, 19270050.
33. Dhillon AS, Tarbutton GL, Levin JL, Plotkin GM, Lowry LK, Nalbone JT, Shepherd S. Pesticide/environmental exposures and Parkinson's disease in East Texas. J Agromedicine 2008, 13:37-48. 10.1080/10599240801986215, 19042691.
34. Hatcher JM, Pennell KD, Miller GW. Parkinson's disease and pesticides: a toxicological perspective. Trends Pharmacol Sci 2008, 29:322-329. 10.1016/j.tips.2008.03.007, 18453001.
35. Landrigan PJ, Sonawane B, Butler RN, Trasande L, Callan R, Droller D. Early environmental origins of neurodegenerative disease in later life. Environ Health Perspect 2005, 113:1230-1233. 10.1289/ehp.7571, 1280407, 16140633.
36. Takahashi M, Yamada T. Viral etiology for Parkinson's disease-a possible role of influenza a virus infection. Jpn J Infect Dis 1999, 52:89-98.
37. Blandini F, Armentero MT, Martignoni E. The 6-hydroxydopamine model: news from the past. Parkinsonism Relat Disord 2008, 14(Suppl 2):124-129.
38. Cicchetti F, Drouin-Ouellet J, Gross RE. Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models?. Trends Pharmacol Sci 2009, 30:475-483. 10.1016/j.tips.2009.06.005, 19729209.
39. Erazi H, Ahboucha S, Gamrani H. Chronic exposure to aluminum reduces tyrosine hydroxylase expression in the substantia nigra and locomotor performance in rats. Neurosci Lett 2011, 487:8-11. 10.1016/j.neulet.2010.09.053, 20884324.
40. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999, 46:598-605. 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F, 10514096.
41. McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2004, 10(Suppl 1):3-7.
42. Barcia C, Ros CM, Annese V, Gomez A, Ros-Bernal F, Aguado-Yera D, Martinez-Pagan ME, de Pablos V, Fernandez-Villalba E, Herrero MT. IFN-γ signalling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. Cell Death Dis 2011, 2:e142. 10.1038/cddis.2011.17, 3122054, 21472005.
43. Mangano EN, Litteljohn D, So R, Nelson E, Peters S, Bethune C, Bobyn J, Hayley S. Interferon-γ plays a role in paraquat-induced neurodegeneration involving oxidative and proinflammatory pathways. Neurobiol Aging 2009, in press.
44. Mount MP, Lira A, Grimes D, Smith PD, Faucher S, Slack R, Anisman H, Hayley S, Park DS. Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci 2007, 27:3328-3337. 10.1523/JNEUROSCI.5321-06.2007, 17376993.
45. Doyle SE, O'Connell R, Vaidya SA, Chow EK, Yee K, Cheng G. Toll-like receptor 3 mediates a more potent antiviral response than Toll-like receptor 4. J Immunol 2003, 170:3565-3571.
46. Jack CS, Arbour N, Manusow J, Montgrain V, Blain M, McCrea E, Shapiro A, Antel JP. TLR signaling tailors innate immune responses in human microglia and astrocytes. J Immunol 2005, 175:4320-4330.
47. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996, 47(Suppl 3):161-170.
48. Gao HM, Liu B, Hong JS. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 2003, 23:6181-6187.
49. Wu DC, Teismann P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, Przedborksi S. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A 2003, 100:6145-6150. 10.1073/pnas.0937239100, 156340, 12721370.
50. Anrather J, Racchumi G, Iadecola C. NF-kappaB regulates phagocytic NADPH oxidase by inducing the expression of gp91phox. J Biol Chem 2006, 281:5657-5667.
51. Babior BM. NADPH oxidase: an update. Blood 1999, 93:1464-1476.
52. Gupta SP, Patel S, Yadav S, Singh AK, Singh S, Singh MP. Involvement of nitric oxide in maneb- and paraquat-induced Parkinson's disease phenotype in mouse: is there any link with lipid peroxidation?. Neurochem Res 2010, 35:1206-1213. 10.1007/s11064-010-0176-5, 20455021.
53. Le W, Rowe D, Xie W, Ortiz I, He Y, Appel SH. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J Neurosci 2001, 12:8447-8455.
54. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999, 5:1403-1409. 10.1038/70978, 10581083.
55. McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, Di Monte DA. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 2002, 10:119-127. 10.1006/nbdi.2002.0507, 12127150.
56. Liu B, Jiang JW, Wilson BC, Du L, Yang SN, Wang JY, Wu GC, Cao XD, Hong JS. Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. J Pharmacol Exp Ther 2000, 295:125-132.
57. Cicchetti F, Lapointe N, Roberge-Tremblay A, Saint-Pierre M, Jimenez L, Ficke BW, Gross RE. Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats. Neurobiol Dis 2005, 20:360-371. 10.1016/j.nbd.2005.03.018, 16242641.
58. Goldman SA. Adult neurogenesis: from canaries to the clinic. J Neurobiol 1998, 36:267-286. 10.1002/(SICI)1097-4695(199808)36:2<267::AID-NEU12>3.0.CO;2-B, 9712309.
59. Im SH, Yu JH, Park ES, Lee JE, Kim HO, Park KI, Kim GW, Park CI, Cho SR. Induction of striatal neurogenesis enhances functional recovery in an adult animal model of neonatal hypoxic-ischemic brain injury. Neuroscience 2010, 169:259-268. 10.1016/j.neuroscience.2010.04.038, 20610036.
60. Kreuzberg M, Kanov E, Timofeev O, Schwaninger M, Monyer H, Khodosevich K. Increased subventricular zone-derived cortical neurogenesis after ischemic lesion. Exp Neurol 2010, 226:90-99. 10.1016/j.expneurol.2010.08.006, 20713052.
61. Parent JM, Vexler ZS, Gong C, Derugin N, Ferriero DM. Rat forebrain neurogenesis and striatal neuron replacement after focal stroke. Ann Neurol 2002, 52:802-813. 10.1002/ana.10393, 12447935.
62. Peng J, Xie L, Jin K, Greenberg DA, Andersen JK. Fibroblast growth factor 2 enhances striatal and nigral neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neuroscience 2008, 153:664-670. 10.1016/j.neuroscience.2008.02.063, 2864598, 18407421.
63. Richardson JR, Quan Y, Sherer TB, Greenamyre JT, Miller GW. Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicol Sci 2005, 88:193-201. 10.1093/toxsci/kfi304, 16141438.